Executive Summary : Swapna Sengupta
Key Take aways from BOAI 2023
Session Sponsorship: Chair-Person:1,
Moderator: 1, Total Panelist: 3
Recommendation: We should increase share of voice of LENVIMA by doing scientific engagements.
Strategy(to drive concept of NASH/NAFLD) is on track and KOL’s are appreciating the same.
Topic: "Viral Vs. Non-viral Etiology: Should It Affect Treatment
Selection in 1L HCC?“
Key Discussion points:
• Dr Amish Vora led the discussion on above the topic and gathered consensus to use LENVATINIB
for Nash related uHCC 1L patients
• In the IMBRAVE 150 subgroup analysis LENVIMA showed better efficacy in non viral uHCC
patients Atezolizumab +Bevacizumab(A+B) was not as effective as it was in other subgroup.
• Meta-analyses(published in Nature) suggest that immunotherapy may be less effective in the
treatment of patients with NAFLD/NASH-associated HCC Immunotherapy promotes NAFLD
associated inflammation and Fibrosis due to its Mode of Action, which further leads to worse
outcome in NAFLD-HCC patients receiving immunotherapy.
• As per real world evidences: In NASH/NAFLD patients LENVATINIB reduced risk by 54%, with
HR .46, P value is 0.0181. OS : LENVATINIB: 21.2 months v/s A+B: 12.2 months.
• This evidence suggest that 1L LENVATINIB may be a preferred treatment choice in patients with
advanced uHCC .
Insight from KOL’s(other than session):
• Last 3 years Eisai does not have any presence in the market. Lack of confidence amongst HCP’s
regarding the Eisai’s presence in Oncology. Happy to see that Eisai still has focus on Oncology,
would like to associate with EISAI in near future.
 Key Take aways from BOAI 2023

Topic: LEAP 002

Key Discussion points:

Adboard: Speaker :1, Moderator: 1, Advisor: 7 • Dr Amit Rauthan led the discussion as moderator and Dr MV Chandrakanth
was presenter in adboard meeting.

• In LEAP 002: OS of LENVIM 19.0 months v/s LEN+ PEM : 21.2 months.
Where in Reflect trial OS of LENVATINIB V/S Sorafenib: 13.6 months v/s 12.3
months. LENVATINIB as a mono therapy showed better efficacy.

• LEN demonstrates the efficacy regardless of etiology in uHCC, data supports

LEN as a standard of care option for pts with 1L uHCC.
• Advisors mentioned that even if it is negative trial it increases their
confidence of LENVATINIB monotherapy.
Photographs